Search
Clinician Ordering Portal
Empowering people, informing care decisions.
At Castle, it all comes down to people. After all, disease doesn’t just happen — it happens to people. We believe that disease management and treatment decisions can be better informed through a person’s unique biology, which is revealed through the scientific rigor of our innovative tests. We are committed to empowering healthcare providers and patients with the goal of improved outcomes.
About UsClinical focus areas
Our broad portfolio of innovative tests focuses on answering critical clinical questions. Our tests are designed to deliver personalized information that better informs care decisions.
Dermatology
Gastroenterology
Ophthalmology
Our tests
Cutaneous Melanoma
Make more confident, more accurate treatment plan decisions for sentinel lymph node biopsy guidance as well as surveillance and therapeutic interventions.
Make more confident, more accurate diagnostic decisions with genomic insight for melanocytic lesions.
Cutaneous Squamous Cell Carcinoma (SCC)
Make more confident, more accurate treatment plan decisions for surveillance and therapeutic interventions.
Barrett’s Esophagus
Go beyond tissue morphology to predict a patient’s individualized risk of progression to esophageal cancer in Barrett’s esophagus.
Uveal Melanoma
Make more informed, risk-aligned treatment plan decisions based on comprehensive molecular profiling.
.svg)
Featured spotlights
-
Castle featured in USA TODAY: Personalized melanoma care powered by 31-GEP
This article, part of the 2025 USA TODAY Skin Health Campaign, highlights how DecisionDx-Melanoma empowers patients and clinicians to co-create individualized care plans based on tumor biology. Featuring patient advocate Leah Bressler, it emphasizes how 31-GEP testing provides both clinical clarity and peace of mind.
-
Prospective, multicenter analysis of RFS after SLN guidance from 31-GEP
This study is a prospective, multi-center study that assessed the effect of 31-GEP testing on SLNB performance rates in patients with T1–T2 tumors considering SLNB and to study long-term outcomes of patients with a Class 1A result (n=130). Of these low-risk patients, 63 had an SLNB, with a 3.2% SLN positivity rate (2/63). No Class 1A patients, regardless of SLN status, experienced a recurrence (2-year median follow-up). These results are consistent with previous studies that the 31-GEP can identify patients at low risk of SLN positivity and recurrence.
-
Metastasis-free survival prediction with the 40-gene expression profile test in patients with cutaneous squamous cell carcinoma risk stratified according to the National Comprehensive Cancer Network Guidelines
Despite definitive surgical treatment, a subset of cutaneous squamous cell carcinomas (cSCC) has an increased risk of regional/distant metastasis making it challenging to identify patients most at risk.1 The 40-gene expression profile (40-GEP) prognostic test improves risk stratification for patients with cSCC with known clinical or histologic risk factors, stratifying patients’ risk of metastasis as low (Class 1), higher (Class 2A), or highest (Class 2B) risk.
-
Case Study: Multiple pigmented lesions with uncertain skin biopsy
Brent Moody, MD, FACP, FAAD discusses how MyPath Melanoma raised red flags in a 26-year-old patient with multiple pigmented lesions.
-
Largest prospective study to date of patients with uveal melanoma further supports performance of DecisionDx-UM for metastatic risk stratification and highlights PRAME as a valuable adjunct biomarker for further risk refinement when considered in conjunction with a DecisionDx-UM result
-
TissueCypher Barrett’s esophagus assay impacts clinical decisions in the management of patients with Barrett’s esophagus
Relentless pursuit of the best outcomes
At Castle, we combine innovation, advanced technologies and relevant real-world evidence to address critical unmet clinical needs and improve health outcomes.
The validity and utility of Castle’s innovative tests has been demonstrated in more than 150 peer-reviewed publications, and more than 300,000 test reports have been delivered to clinicians since 2008 to guide improved disease management decisions for patients.
The latest
News
Press Release
Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov....
Press Release
Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The...
Press Release
Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award
We are transforming disease management. Join in the transformation.
Every employee at Castle has an impact on patient care. If you are interested in making a difference in the lives of patients while doing something that inspires you, find out what exciting opportunities are available within our team.
